Hansa Biopharma — Oktober 2024
-
Hansa Biopharma: Improved use cases
Currently, Hansa Biopharma is trading above Redeye's Bear Case. We engaged in a discussion with analyst Johan Unnerus about the latest earnings report, cost-savings vs expansion and other relevant topics.
god weekend ... Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind